

January 2026

Investor Presentation

Nasdaq: ASBP





Safe Harbor Statement

This presentation contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this presentation is as of the date of this presentation. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this presentation.



Aspire at a Glance

Patent-pending drug delivery technology for rapid sublingual absorption and entry into the bloodstream of drugs and supplements

- Enhances the pharmacokinetic performance of Active Pharmaceutical Ingredients (“APIs”), supplements and nutraceuticals into the bloodstream, increasing bioavailability, improving speed of onset and reducing side effects
- Multiple Rx applications in heart attack/stroke, anxiety, antiplatelet, nausea, and others
- Application in multiple oral/intraoral product formats such as tablets, capsules, oral suspensions, and others
- Omnibus patent and four provisional patents filed for approved therapeutics in multi-billion dollar markets
- Contract Manufacturing Relationships
- Lead Rx Product: Sublingual High Dose Aspirin
- Lead Consumer Product: BUZZ BOMB™ Sublingual Caffeine
- Focused on commercialization through partnerships, licensing and internal development
- Investment Considerations:
 - > *Mid-Stage Biotech Company*
 - > *Several Products in Development*
 - > *First Revenues Earned in Q3 2025 from BUZZ BOMB™*
- Market Opportunity: >\$100 billion




Drug and Supplement Delivery Technology Innovator



Aspire Biopharma has developed disruptive technologies for delivering drugs and other products sublingually⁽¹⁾.



Technology delivers fast acting drug formulations using our patent-pending methodology, and proprietary process.



New mechanism of delivery allows rapid sublingual absorption into the bloodstream.

(1) Aspire filed a patent application (No. PCT/US2024/022318) on March 29, 2024 for its low-dose aspirin. Aspirin filed a second patent on October 2, 2024 (No. 63/702,381) for its high-dose aspirin.



Drug and Supplement Delivery Technology Innovator

01

Fast Acting

Powder-form medication developed using our patent-pending technology enters the bloodstream in a fraction of the time as compared to oral tablets and capsules

02

Easy to Use

Dissolves easily under the tongue

03

Dosage Management

Drugs avoid first pass through the liver and are not metabolized like swallowed products

04

Bypasses the Digestive Tract

Reduces or eliminates adverse reactions in the gastrointestinal tract

05

Replaces pills and tablets

Easy for patient or caregiver to administer



Aspire's Mechanisms of Action


Nature Provides the Mouth with Direct Access to Blood Stream

Aspire's sublingual delivery system avoids the side effect drugs delivered in pills or tablets orally

- Avoid damage to GI tract
- Avoid damage to the Liver

The most common set of side effects for drugs involves the gastrointestinal system

Mouth to Blood Stream Pathways




1. The main artery is the lingual artery
2. Tonsillar branch of the facial artery
3. Ascending pharyngeal artery

The veins drain into the internal jugular vein



Overview – The Technology

ASPIREBIOLABS.COM



[Aspire's Patent Pending Sublingual Technology Video](#)



Aspire Pipeline, Commercial Opportunities & Planned 2026 Milestones

Aspirin Products

High Dose

- ✓ **Completed clinical trial to evaluate the pharmacodynamic effect of a single dose of acetylsalicylic acid 162 mg sublingual powder (OTASA) on platelet inhibition compared to that of standard oral aspirin in July 2025.**
- ✓ **FDA response letter supports 505(b)(2) filing in H2 2026.**
- ✓ **No additional studies required beyond current planned 32-subject clinical trial.**

- Based on FDA's feedback, Aspire anticipates completing a currently planned multicenter crossover clinical trial in middle of 2026 and then submitting a Section 505(b)(2) New Drug Application for emergency treatment of myocardial infarction.

- The clinical trial will evaluate serum thromboxane B₂ (TxB₂) inhibition in

Non-Aspirin Prescription Drug Products

- Alprazolam (Generic Xanax®): Formulation for sublingually administration of drug for treatment of anxiety ; Phase 1 clinical trial planned for mid-2026. Provisional patent filed January 2026.
- Clopidogrel (Generic Plavix®): Antiplatelet to prevent blood clots. Provisional patent filed January 2026.
- Ondansetron (Generic Zofran®): Antiemetic medication that prevents nausea and vomiting from chemotherapy, radiation, and surgery. Provisional patent filed January 2026. Phase 1 clinical trial planned for late 2026.
- Meclizine: Antihistamine used primarily to prevent and treat motion sickness (nausea, vomiting, dizziness) and vertigo. Provisional patent filed February 2026.

Non-Prescription Products

- ✓ **Launched BUZZ BOMB™ single dose pre-workout caffeine supplement utilizing sublingual delivery technology.**
- ✓ **Pre-workout supplement features 50mg of caffeine designed to support sustained energy and mental focus; helps athletes and fitness enthusiasts maximize performance**



Aspire Patent Portfolio

Sublingual Aspirin Product Candidate

- Filed provisional patent applications with the USPTO on March 31, 2023 and October 2, 2024, respectively, pertaining to Oral Mucosal Formulations of Aspirin that utilize Aspire's fast acting formulation.

Omnibus Patent Filing

- Filed an omnibus patent application with the U.S. Patent and Trademark Office ("USPTO") for its sublingual delivery technology October 2025.
- Application seeks patent protection of Aspire's proprietary technology in a variety of classes of drugs and other substances focusing exclusively on protecting the Company's advanced sublingual drug delivery system,
- An omnibus claim is a statement in a patent application that describes the unique features of an invention and defines the scope of protection for the patent. It is a formal way of summarizing the points of novelty of the invention and is usually followed by a fixed form. The omnibus patent can provide IP protection in new areas/classes in addition to the patents already filed by Aspire.

Non-Aspirin Drug Product Candidate Patents Filed January 2026

- Alprazolam (Generic Xanax®): Formulation for sublingually administration of drug for treatment of anxiety. Provisional patent filed January 2026.
- Clopidogrel (Generic Plavix®): Antiplatelet to prevent blood clots. Provisional patent filed January 2026.
- Ondansetron (Generic Zofran®): Antiemetic medication that prevents nausea and vomiting from chemotherapy, radiation, and surgery. Provisional patent filed January 2026.
- Meclizine: Antihistamine used primarily to prevent and treat motion sickness (nausea, vomiting, dizziness) and vertigo. Provisional patent filed February 2026.



Global Market Opportunity for Target Product Portfolio

Aspire believes its disruptive technology can be applied to a number of approved drugs and supplements

Global Analgesics Market

Valued at **\$47.32B** in 2023 and projected to reach **\$75.73B** by 2032, growing at a compound annual growth rate (CAGR) of 5.39% over the forecast period 2024-2032. (Source: SNS Insider)

Global Clopidogrel Market (Plavix and Generics)

The total market (brand + generics) for clopidogrel was around **\$11.87B** in 2024 and is forecast to reach **\$19.65B** by 2029, growing at about 10.5% CAGR. (Source: Research & Markets)

Global Alprazolam Market (Xanax and Generics)

Valued at **\$34.93B** in 2023, the market is expected to grow at a CAGR of 5.4% during the period 2024-2032, reaching **\$55.84B** by 2032.

Global Ondansetron Market (Zofran and Generics)

Valued at approximately **\$1.4B** in 2023 and projected to reach **\$2.4B** by 2032, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period. (Source: DataIntelto)

Global Meclizine Hydrochloride Market

Valued at approximately **\$450M** in 2023, and it is projected to reach **\$650M** by 2032, growing at a CAGR of 4.1% during the forecast period. (Source: DataIntelto)

Global Pre-Workout Market

Supplements market valued at **\$19.90B** in 2023. Estimated to reach **\$29.77B** by 2032, growing at a CAGR of 4.58% during the forecast period (2024–2032). (Source: Straits Research)



Sublingual Aspirin Product: Background

01

Oral aspirin (ASA) with its anti-inflammatory properties has been used world-wide for over 100 years

02

Aspirin is one of the most-studied and understood drugs and universally approved for use.

03

In the past Aspirin-induced GI bleeding has limited the long-term oral use and is severely diluted by first pass metabolism by the liver

Aspire's sublingual aspirin is expected to provide fast absorption, eliminate the GI tract side effects, and avoid first pass liver metabolism



Sublingual Aspirin Product: Clinical Trial

Strategy

Aspire uses existing, approved generic-drug dosages. Generic drugs do not need to repeat the clinical trials related to active ingredients but must demonstrate sublingual route of administration as it pertains to:

- effectiveness
- amount of drug that gets to the bloodstream and
- time it takes to get there

Trial Summary

Investigational sublingual aspirin product for treatment of suspected acute myocardial infarction (AMI, blockage of blood flow to heart muscle causing damage or death of heart tissue – commonly known as a “heart attack”). There are an estimated 18 million Americans living with coronary artery disease with approximately 800,000 per year experiencing an AMI leading to 300,000 deaths.

Clinical Trial Timeline

First patient dosed: June 2025

Trial completed end of July 2025

Results

Aspire’s sublingual aspirin achieved therapeutic doses **at least five times faster** than chewable aspirin tablets






Sublingual Aspirin Product: Overview and Top-Line Clinical Results

Study Design and Top-Line Results

- Primary objective of the clinical trial was to evaluate the bioavailability of acetylsalicylic acid (ASA, the active antiplatelet form of aspirin) in plasma over eight hours after dosing.
- Randomized, crossover bioavailability trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Aspire's investigational new powder formulation sublingual aspirin product compared to chewed uncoated aspirin tablets in healthy adults.
- Aspire sublingual aspirin product produced higher and more rapid mean plasma concentrations of ASA, compared to chewed aspirin tablets.
- Significant improvement in absorption was evident within five minutes and continued throughout the first half-hour after dosing.
- Achieved therapeutic doses 2-3 times faster than chewable aspirin tablets.**
- Aspire product was safe and well-tolerated by patients, and no adverse events were reported.

Benefits of "rapid absorption" aspirin

- Address and limit heart attack and stroke.
- Allow high dose absorption for pain management including quick headache relief, post surgery, cancer pain management, and general pain relief.






Sublingual Aspirin Product: Overview and Top-Line Clinical Results

ASPIREBIOLABS.COM

Additional Important Clinical Trial Findings

- Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing
- TxB2 is a biomarker indicating aspirin's effect on platelet aggregation, the clumping of platelets that leads to dangerous blood clots; average person has concentration at 120 ng/mL.
- This rapid inhibition is critical during suspected heart attacks, when clots blocking heart arteries can cause permanent muscle damage
- Lab results showed Aspire's product acted more than five times as fast as the current recommendation for chewed aspirin tablet treatment
- Positive FDA response letter to Aspire's pre-IND submission**
- Anticipates conducting the final clinical trial in middle of 2026, followed by its 505(b)(2) application in second half 2026.**

Mean Serum TxB2* Concentrations (ng/mL) (lower concentrations mean less platelet aggregation) over 30 Minutes after Dosing OTASA BA2038 (Aspire sublingual aspirin granules), OTASA BA002039 (Aspire sublingual aspirin powder) or Chewed ASA Tablets (chewable)



* TxB₂ is a stable metabolite of thromboxane A₂ (TxA₂), a potent chemical that promotes platelet clumping and vasoconstriction. Measuring low levels of TxB₂ confirms that aspirin is working as intended



Sublingual Aspirin Product Commercialization and Go-to-Market Strategy

01

Launch product initially in the Rx market, likely through licensing or partnering agreements

02

Partner with an experienced end-to-end marketing and distribution firms

03

Significant potential licensing opportunities with leading drug manufacturers (cited in the recent McKinsey study)



Sublingual Aspirin Product: Analgesics Market Opportunity

Non-opioid analgesic and opioid markets combined currently estimated at \$80+B and projected to grow to nearly \$100B in five years

		2022	2023	2024	2025	2026	2027
Market Data (\$-Bil)							
	Opioids	\$32.5	\$33.6	\$34.6	\$35.7	\$36.8	\$37.9
	Analgesics	\$48.0	\$50.3	\$52.7	\$55.2	\$58.0	\$61.0
	Analgesics Market Total (incl. Opioids)	\$80.4	\$83.8	\$87.3	\$90.9	\$94.8	\$98.9
	RX \$	\$68.4	\$71.3	\$75.1	\$79.0	\$83.4	\$88.0



BUZZ BOMB™ New Sublingual Caffeine Supplement

Single serving 50mg caffeine supplement utilizing Aspire's patent-pending and proprietary sublingual delivery technology


- Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the caffeine market
- Initial production of four flavor options, several new flavors to be brought to market in 2026
- Marketing focused on cost-effective multi-channel digital strategy targeting primary influencers, direct response sales and traditional retail sales channel
- Aspire has partnered with well-known athletes and influencers across fitness training and endurance sports to accelerate consumer awareness and uptake
- BUZZ BOMB™ is available for purchase at buzzbombcaffeine.com, the Company's new E-commerce website

Global pre-workout supplements market size is expected to reach \$27.97B by 2030, registering a CAGR of 5.9% from 2025 to 2030



BUZZ BOMB™ New Sublingual Caffeine Supplement

ASPIRELABS.COM



New BUZZ BOMB™ E-Commerce Website Landing Page



BUZZ BOMB™ Newly Designed Packaging




BUZZ BOMB™ Disruptive Characteristics

BUZZ BOMB™ Caffeine Supplement Benefits:

- **Speed:** works nearly immediately (less than 2 minutes) vs. 20-30 minutes
- **Convenience:** small, easy to use single-use packets (no mixing and measuring for beverages)
- **Energy management:** use as needed to precisely manage caffeine intake (50mg increments)
- **Single Safe Active Ingredient** : well-known benefits and use of caffeine
- **Low manufacturing & packaging costs:** competitive pricing with high margin potential

ASPIREBIOLABS.COM





BUZZ BOMB™ Buzz at the Fitness Conventions

ASPIRELABS.COM



Shop FAQ Blog

**QUICK EASY
CAFFEINE**

Pocket-sized, all-natural clean caffeine with no crash.

[SHOP NOW](#)

GOOD CLEAN ENERGY

- SUGAR FREE
- INSTANT ENERGY
- GMO FREE
- ORGANICALLY SOURCED
- FAST REFORMING
- NO CRASH



Pre-Workout Supplement Market

- Global pre-workout supplements market size is expected to reach \$27.97 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030 driven by:
 - ❖ Rising fitness culture and gym memberships
 - ❖ Consumer focus on performance and recovery
 - ❖ Expanding demographics (women, Gen Z, casual exercisers)
 - ❖ Growth of RTD ("Ready To Drink"- no mixing) formats & natural formulations
 - ❖ Digital fitness and influencer-led marketing
- Segment is flooded with many options for energy boosting and hydration products.
- Most products today are based on a powdered "mix + water" combination that take 20-30 minutes to digest and begin to provide performance benefits.
- Complicates use, response management, caffeine control, and effectiveness.
- Market research shows that immediacy, ease of use and time management (take as needed, when needed) ranks highest in consumer preferences.

BUZZ BOMB™ offers potentially disruptive benefits and product characteristics that is expected to drive market penetration with significant differentiation, leading to rapid customer conversion, acquisition, and brand identity in this market.



Aspire's Investment Considerations

- **Multiple Rx applications** in heart attack/stroke, anti-anxiety, antiplatelet, nausea and others
- **Large Addressable Rx Markets**
- **High Dose Aspirin Prescription Product:** *Trial demonstrated dramatically higher and more rapid therapeutic impact compared to standard chewed aspirin tablets, safe and well-tolerated. Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing. This rapid inhibition is critical during suspected heart attacks, when clots blocking heart arteries can cause permanent muscle damage.*
- **Expect to file FDA 505 (b)(2) Fast Track drug approval process in second half of 2026 , and will seek breakthrough therapy designation**
- **First to market:** Prescription strength version potentially followed by OTC
- **Omnibus patent, aspirin tablets and four provisional patents filed for approved therapeutics in multi-billion dollar markets**
- **BUZZ BOMB™, New Sublingual Pre-Workout Supplement Launched in Q3 2025: Commercial revenue in 2025 with new e-commerce website, packaging and product launched January 2026**
- **Global pre-workout supplements market size expected to reach \$27.97 billion by 2030**
- **Focused on commercialization through partnerships, licensing and internal development**
- **Proprietary Patent-Pending Technology:** Enables ability to pursue broadened applications using our solubility process which can

Thank You.



Aspire BioPharma Holdings, Inc.
23150 Fashion Drive, Suite 232
Estero, FL 33928

www.aspirebiolabs.com
info@aspire-biopharma.com

Investor Relations
Kevin McGrath
PCG Advisory
kevin@pcgadvisory.com

Nasdaq: ASBP